FIGURE 1

FIGURE 2A

# FIGURE 2B

FIGURE 3A

FIGURE 3B

FIGURE 4A

FIGURE 4B

FIGURE 5A

FIGURE 5B

FIGURE 6A

FIGURE 6B

FIGURE 7A

FIGURE 7B

Tumor Weight (mg)

FIGURE 8A

FIGURE 8B

Tumor Weight(mg)

FIGURE 9

**Weight of Human Colon Adenocarcinoma (HT-29) in CD-1
Nude Mice Treated with Combination Therapy**

FIGURE 10

Weight of Human Colon Adenocarcinoma (HT-29) in CD-1 Nude Mice

* means P < 0.05

FIGURE 11

Growth of Human Colon Adenocarcinoma (HT-29) in CD-1 Nude Mice

FIGURE 12

Growth of Human Adenocarcinoma (HT-29) in CD-1 Nude Mice

FIGURE 13

FIGURE 14

**Weight of Human Prostate Carcinoma (PC-3)
in SCID Mice**

A

B

FIGURE 15

Weight of Human Prostate Carcinoma(DU145) in SCID Mice

A

B

FIGURE 16

Weight of Human Melanoma (A2058) in CD-1 Nude Mice

FIGURE 17

Weight of Human Breast Adenocarcinoma (MDA-MB-231) in CD-1 Nude Mice

A

B

Growth of Human Breast Adenocarcinoma (MDA-MB-231) in CD-1 Nude Mice

C

FIGURE 18

Growth of Human Ovary Adenocarcinoma (SK-OV-3) in CD-1 Nude Mice

FIGURE 19

A   **Growth of Human Pancreatic Carcinoma (BxPC-3) in CD-1 Nude Mice**

B   **Weight of Human Pancreatic Carcinoma (BxPC-3) in CD-1 Nude Mice**

FIGURE 20

Growth of Human Cervix Epitheloid Carcinoma (Hela S3-HU-Resistance) in SCID Mice

Weight of Human Cervix Epitheloid Carcinoma (Hela S3-HU-Resistance) in SCID Mice

FIGURE 21

Weight of Human Cisplatin-Resistant Breast Adenocarcinoma Implanted at the Fat Pad of SCID Mice

Statistical Analysis:	P value
Saline : Cisplatin	0.0834
Saline : Taxol	<0.0001
Saline : SEQ ID NO:1	<0.0001
SEQ ID NO:1 : Cisplatin	0.0007
SEQ ID NO:1 : Taxol	0.9547

FIGURE 22

Growth Of Human Breast Cancer (MDA-CDDP-S4) In CB-17 SCID Mice Treated With Taxol, SEQ ID NO:1, and Taxol+ SEQ ID NO:1 (Orthotopical transplant)

A

B

C

SEQ ID NO:1: Taxol P=0.0133
SEQ ID NO:1: SEQ ID NO:1+Taxol P=0.0003
Taxol : SEQ ID NO:1+Taxol P<0.0001

FIGURE 23

**Weight of Human Taxol-Resistant Breast Adenocarcinoma
(MDA-MB435-To.1) Implanted at the Fat Pad of SCID Mice**

A

B

Tumor Weight (mg)

FIGURE 24

Growth of Human Breast Adenocarcinoma (MDA-MB435-To. 1) in SCID Mice

A

Weight of Human Breast Adenocarcinoma (MDA-MB-435-To. 1) in SCID Mice

B

FIGURE 25

**Growth of Promyelocytic Leukemia HL-60
(Taxol-Resistant) in SCID Mice**

A

**Weight of Human Promyelocytic Leukemia HL-60
(Taxol-Resistant) in SCID Mice**

B

FIGURE 26

Growth of Human Multi-Drug Resistance Colon Adenocarcinoma (LS513) in SCID Mice

A

B

Weight of Human Colon Multi-Drug Resistance Carcinoma (LS513) in SCID Mice

C

FIGURE 27

>gi|4557844|ref|NM_001034.1| Homo sapiens ribonucleotide reductase M2
polypeptide (RRM2), mRNA

CCCAGGCGCAGCCAATGGGAAGGGTCGGAGGCATGGCACAGCCAATGGGAAGGGGCCGGGGCACCAAAGCC
AATGGGAAGGGCCGGGAGCGCGCGGCGCGGGAGATTTAAAGGCTGCTGGAGTGAGGGGTCGCCCGTGCAC
CCTGTCCCAGCCGTCCTGTCCTGGCTGCTCGCTCTGCTTCGCTGCGCCTCCACTATGCTCTCCCTCCGTG
TCCCGCTCGCGCCCATCACGGACCCGCAGCAGCTGCAGCTCTCGCCGCTGAAGGGGCTCAGCTTGGTCGA
CAAGGAGAACACGCCGCCGGCCCTGAGCGGGACCCGCGTCCTGGCCAGCAAGACCGCGAGGAGGATCTTC
CAGGAGCCCACGGAGCCGAAAACTAAAGCAGCTGCCCCCGGCGTGGAGGATGAGCCGCTGCTGAGAGAAA
ACCCCGCCGCTTTGTCATCTTCCCCATCGAGTACCATGATATCTGGCAGATGTATAAGAAGGCAGAGGC
TTCCTTTTGGACCGCCGAGGAGGTTGACCTCTCCAAGGACATTCAGCACTGGGAATCCCTGAAACCCGAG
GAGAGATATTTTATATCCCATGTTCTGGCTTTCTTTGCAGCAAGCGATGGCATAGTAAATGAAAACTTGG
TGGAGCGATTTAGCCAAGAAGTTCAGATTACAGAAGCCCGCTGTTTCTATGGCTTCCAAATTGCCATGGA
AAACATACATTCTGAAATGTATAGTCTTCTTATTGACACTTACATAAAAGATCCCAAAGAAAGGGAATTT
CTCTTCAATGCCATTGAAACGATGCCTTGTGTCAAGAAGAAGGCAGACTGGGCCTTGCGCTGGATTGGGG
ACAAAGAGGCTACCTATGGTGAACGTGTTGTAGCCTTTGCTGCAGTGGAAGGCATTTTCTTTTCCGGTTC
TTTTGCGTCGATATTCTGGCTCAAGAAACGAGGACTGATGCCTGGCCTCACATTTTCTAATGAACTTATT
AGCAGAGATGAGGGTTTACACTGTGATTTTGCTTGCCTGATGTTCAAACACCTGGTACACAAACCATCGG
AGGAGAGAGTAAGAGAAATAATTATCAATGCTGTTCGGATAGAACAGGAGTTCCTCACTGAGGCCTTGCC
TGTGAAGCTCATTGGGATGAATTGCACTCTAATGAAGCAATACATTGAGTTTGTGGCAGACAGACTTATG
CTGGAACTGGGTTTTAGCAAGGTTTTCAGAGTAGAGAACCCATTTGACTTTATGGAGAATATTTCACTGG
AAGGAAAGACTAACTTCTTTGAGAAGAGAGTAGGCCGAGTATCAGAGGATGGGAGTGATGTCAAGTCCAAC
AGAGAATTCTTTTACCTTGGATGCTGACTTCTAAATGAACTGAAGATGTGCCCTTACTTGGCTGATTTTT
TTTTTCCATCTCATAGGAAAAATCAGCTGAAGTGTTAACCTAGCCACACCCATGAATTGTCCGTAATGT
TCATTAACAGCATCTTTAAAAACTGTGTAGCTACCTCACAACCAGTCCTGTCTGTTTATAGTGCTGGTAGT
ATCACCTTTTGCCAGAAGGCCTGGCTGGCTGTGACTTACCATAGCAGTGACAATGGCAGTCTTGGCTTTA
AAGTGAGGGGTGACCCTTTAGTGAGCTTAGCACAGCGGGATTAAACAGTCCTTTAACCAGCACAGCCAGT
TAAAAGATGCAGCCTCACTGCTTCAACGCAGATTTTAATGTTTACTTAAATATAAACCTGGCACTTTACA
AACAAATAAACATTGTTTTGTACTCACGGCGGCGATAATAGCTTGATTTATTTGGTTTCTACACCAAATA
CATTCTCCTGACCACTAATGGGAGCCAATTCACAATTCACTAAGTGACTAAAGTAAGTTAAACTTGTGTA
GACTAAGCATGTAATTTTTAAGTTTTATTTTAATGAATTAAAATATTTGTTAACCAACTTTAAAGTCAGT
CCTGTGTATACCTAGATATTAGTCAGTTGGTGCCAGATAGAAGACAGGTTGTGTTTTTATCCTGTGGCTT
GTGTAGTGTCCTGGGATTCTCTGCCCCCTCTGAGTAGAGTGTTGTGGGATAAAGGAATCTCTCAGGGCAA
GGAGCTTCTTAAGTTAAATCACTAGAAATTTAGGGGTGATCTCGGGCCTTCATATGTGTGAGAAGCCGTTT
CATTTTATTTCTCACTGTATTTTCCTCAACGTCTGGTTGATGAGAAAAAATTCTTGAAGAGTTTTCATAT
GTGGGAGCTAAGGTAGTATTGTAAAAATTTCAAGTCATCCTTAAACAAAATGATCCACCTAAGATCTTGCC
CCTGTTAAGTGGTGAAATCAACTAGAGGTGGTTCCTACAAGTTGTTCATTCTAGTTTTGTTTGGTGTAAG
TAGGTTGTGTGAGTTAATTCATTTATATTTACTATGTCTGTTAAATCAGAAATTTTTTATTATCTATGTT
CTTCTAGATTTTACCTGTAGTTCATAAAAAAAAAAAAAAAAAAAAAAAAAAA